Related Experiment Video

Updated: Jan 5, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

Star-PAP regulates tumor protein D52 through modulating miR-449a/34a in breast cancer

Aizhu Duan1,2, Lingmei Kong1, Tao An1

  • 1State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, P.R. China.

Biology Open
|October 26, 2019
PubMed

Insights

Star-PAP, a poly (A) polymerase, inhibits breast cancer progression by downregulating tumor protein D52 (TPD52) through microRNA-449a/34a (miR-449a/34a). This identifies Star-PAP as a potential therapeutic target for breast cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Tumor protein D52 (TPD52) is an oncogene implicated in various cancers.
  • MicroRNA-449a and microRNA-34a (miR-449a/34a) are tumor suppressors targeting TPD52 in breast cancer.
  • The upstream regulators of miR-449a/34a and TPD52 in breast cancer remain unclear.

Purpose of the Study:

  • To investigate the role of Star-papillary (Star-PAP) in regulating miR-449a/34a and TPD52 expression in breast cancer.
  • To elucidate the molecular mechanism by which Star-PAP influences breast cancer tumorigenesis.

Main Methods:

  • Correlation analysis of TPD52 and Star-PAP expression in breast cancer.
  • Overexpression and knockdown studies of Star-PAP.
  • RNA immunoprecipitation and pull-down assays to determine molecular interactions.
  • Rescue experiments involving TPD52 and miR-449a/34a modulation.

Main Results:

  • A negative correlation was observed between TPD52 and Star-PAP expression.
  • Star-PAP overexpression decreased TPD52 levels, while Star-PAP knockdown increased them.
  • Star-PAP directly binds to the 3' region of miR-449a, independent of TPD52.
  • Modulation of Star-PAP, miR-449a/34a, and TPD52 affected cell proliferation and apoptosis.

Conclusions:

  • Star-PAP acts as a tumor suppressor in breast cancer by negatively regulating TPD52 expression via miR-449a/34a.
  • This pathway represents a novel molecular mechanism in breast cancer development.
  • Star-PAP emerges as a potential therapeutic target for breast cancer treatment.
Keywords:
Breast cancerStar-PAPTPD52miR-34amiR-449a

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.0K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K